Castle Biosciences, Inc. (CSTL)
| Market Cap | 737.02M +38.4% |
| Revenue (ttm) | 339.92M -2.1% |
| Net Income | -12.83M |
| EPS | -0.44 |
| Shares Out | 30.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,043,840 |
| Open | 22.67 |
| Previous Close | 22.91 |
| Day's Range | 22.67 - 24.34 |
| 52-Week Range | 14.59 - 44.28 |
| Beta | 1.02 |
| Analysts | Strong Buy |
| Price Target | 43.56 (+79.26%) |
| Earnings Date | Aug 3, 2026 |
About CSTL
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasi... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for CSTL stock is "Strong Buy." The 12-month stock price target is $43.56, which is an increase of 79.26% from the latest price.
News
Castle Biosciences’ i31-SLNB outperforms MIA nomogram in lymph node biopsy
Castle Biosciences (CSTL) announced the publication of a prospective, multicenter study in Dermatology and Therapy demonstrating that DecisionDx-Melanoma’s integrated sentinel lymph node biopsy test r...
DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy
Newly published prospective study shows DecisionDx-Melanoma's i31-SLNB test result more accurately identifies patients at low and high risk of sentinel lymph node (SLN) positivity than the Melanoma In...
Roth starts Castle Biosciences at Buy, notes quality revenue growth outlook
Roth Capital initiated coverage of Castle Biosciences (CSTL) with a Buy rating and $40 price target The firm believes Castle should be owned for its quality revenue growth outlook over…
Castle Biosciences initiated with a Buy at Roth Capital
Roth Capital initiated coverage of Castle Biosciences (CSTL) with a Buy rating and $40 price target
Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal
Stokes was one of 22 financial leaders recognized in the Greater Houston area FRIENDSWOOD, Texas, June 23, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health thro...
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FRIENDSWOOD, Texas, June 19, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on June 15,...
Castle Biosciences’ TissueCypher Test surpasses 100,000 orders
Castle Biosciences (CSTL)’ TissueCypher Barrett’s Esophagus Test has surpassed 100,000 clinical test orders. TissueCypher is an AI-derived precision medicine test designed to predict a patient’s five-...
First Patient Enrolled in New Study Assessing early prediction of flares in Atopic Dermatitis by Castle Biosciences in Collaboration with SciBase
STOCKHOLM, June 10, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-powered skin health solutions, today announced that the first patient has been enrolled i...
Castle Biosciences Transcript: Jefferies Global Healthcare Conference 2026
Strong Q1 growth in core diagnostic tests led to raised 2026 revenue guidance and robust margins. New product launches and pipeline innovations target dermatology and GI markets, while legislative trends and clinical value support future reimbursement and adoption.
Castle Biosciences price target lowered to $35 from $50 at KeyBanc
KeyBanc lowered the firm’s price target on Castle Biosciences (CSTL) to $35 from $50 and keeps an Overweight rating on the shares.
Castle Biosciences price target lowered to $40 from $50 at BTIG
BTIG lowered the firm’s price target on Castle Biosciences (CSTL) to $40 from $50 and keeps a Buy rating on the shares. The company delivered a solid 10% revenue beat…
Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
FRIENDSWOOD, Texas, May 13, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executiv...
Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation
This marks the fifth MedTech Breakthrough Award that Castle has earned for its innovative testing solutions FRIENDSWOOD, Texas, May 12, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a ...
Castle Biosciences reports Q1 EPS , consensus (49c)
Reports Q1 revenue $83.7M, consensus $79.23M. “The Castle Biosciences (CSTL) team delivered outstanding results to start 2026, delivering $83.7M in revenue,” said CEO Derek Maetzold. “Our momentum thi...
Castle Biosciences raises 2026 revenue view to $345M-$355M from $340M-350M
2026 revenue consensus $345.73M.
Castle Biosciences Earnings Call Transcript: Q1 2026
Q1 2026 saw strong revenue and test volume growth, with record months for core products and improved margins. Full-year guidance was raised, and new clinical data reinforced product value. Reimbursement clarity for AdvanceAD-Tx is expected by Q3, with material revenue anticipated in 2027–2028.
Castle Biosciences Slides: Q1 2026
Castle Biosciences has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Castle Biosciences Quarterly report: Q1 2026
Castle Biosciences has published its Q1 2026 quarterly earnings report on May 6, 2026.
Castle Biosciences Earnings release: Q1 2026
Castle Biosciences released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Castle Biosciences Reports First Quarter 2026 Results
Delivered Q1 2026 revenue of $83.7 million Q1 2026 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ®) increased 36% over Q1 2025 Raising full-year 2026 revenue g...
Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month
Longstanding collaborations with AIM at Melanoma, the Melanoma Research Foundation, The Skin Cancer Foundation, IMPACT Melanoma and The Sun Bus continue to advance awareness and education throughout M...
New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's Esophagus
Clinical studies from Mayo Clinic researchers demonstrate the TissueCypher test provides improved risk stratification and influences risk-aligned surveillance decisions in clinical practice, with one ...
Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS
Multi-center clinical and population-based data show that DecisionDx-Melanoma identifies biologically high-risk patients—including those with thin and early-stage disease—and provides recurrence risk ...
Castle Biosciences price target lowered to $40 from $50 at Canaccord
Canaccord analyst Kyle Mikson lowered the firm’s price target on Castle Biosciences (CSTL) to $40 from $50 and keeps a Buy rating on the shares. The firm updated its model…
Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026
FRIENDSWOOD, Texas, April 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will re...